Ojha Utkarsh, Parikh Manish, Patel Vinod
Royal Brompton & Harefield Hospitals, London, UK.
NewYork-Presbyterian Columbia University Irving Medical Center, NY 10032, USA.
Future Cardiol. 2023 Mar;19(4):203-210. doi: 10.2217/fca-2022-0098. Epub 2023 Jun 30.
Hypertrophic obstructive cardiomyopathy (HOCM) affects approximately 1 in 500 people globally. The condition results in hypertrophy of the interventricular septum and thickening of the left ventricular wall. Surgical management to resect the thickened myocardium or septal alcohol ablation are currently considered the mainstay treatment option for HOCM refractory to pharmacological therapy. In this special report we aim to highlight the current landscape of septal mass reduction in HOCM. Next, we describe the evolving discipline of minimally invasive techniques for reducing outflow tract obstruction in patients with HOCM. We further consider future options and outline a possible percutaneous approach for septal myectomy with a novel device.
肥厚型梗阻性心肌病（HOCM）在全球约每500人中就有1人受影响。该病会导致室间隔肥厚和左心室壁增厚。切除增厚心肌的手术治疗或间隔酒精消融目前被认为是药物治疗难治性HOCM的主要治疗选择。在本专题报告中，我们旨在突出HOCM中减少间隔肿块的当前情况。接下来，我们描述用于减少HOCM患者流出道梗阻的微创技术这一不断发展的学科。我们进一步考虑未来的选择，并概述一种使用新型装置进行间隔心肌切除术的可能经皮方法。
